patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_367113 | REC_0012101 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 27 | 4.9 | 67 | male | 0 | 56 | 5.3 | 0 | carboplatin + paclitaxel + pembrolizumab | 49.7 | false | MSS | 2026-03-15T05:35:59.889579+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765860 | REC_0012102 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 18.4 | 63 | male | 1 | 13 | 7 | 4 | entrectinib 600 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:59.889813+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536544 | REC_0012103 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 14 | 13.1 | 65 | female | 0 | 4 | 5.3 | 1 | sotorasib 960 mg daily | 14.5 | true | MSS | 2026-03-15T05:35:59.890047+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482581 | REC_0012104 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 6.8 | 65 | female | 1 | 47 | 5.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.9 | false | MSS | 2026-03-15T05:35:59.890328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280380 | REC_0012105 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 7.9 | 61 | female | 1 | 22 | 4.7 | 1 | osimertinib 80 mg daily | 18.3 | true | MSS | 2026-03-15T05:35:59.890566+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860703 | REC_0012106 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 5.3 | 72 | female | 1 | 14 | 6.3 | 5 | pembrolizumab 200 mg q3w | 13.3 | true | MSS | 2026-03-15T05:35:59.890797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136193 | REC_0012107 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 15.7 | 73 | female | 1 | 24 | 6 | 7 | pembrolizumab 200 mg q3w | 15.1 | true | MSS | 2026-03-15T05:35:59.891028+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_508427 | REC_0012108 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 17.1 | 67 | female | 1 | 12 | 4.5 | 5 | entrectinib 600 mg daily | 6 | false | MSS | 2026-03-15T05:35:59.891262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_483392 | REC_0012109 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 10.4 | 50 | female | 0 | 10 | 6.7 | 6 | osimertinib 80 mg daily | 10.5 | true | MSS | 2026-03-15T05:35:59.891497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224914 | REC_0012110 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 8.3 | 83 | male | 1 | 22 | 3 | 4 | osimertinib 80 mg daily | 6.1 | false | MSS | 2026-03-15T05:35:59.891731+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_426869 | REC_0012111 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 37 | 6.5 | 73 | female | 2 | 73 | 9.1 | 0 | carboplatin + paclitaxel + pembrolizumab | 39 | true | MSS | 2026-03-15T05:35:59.891958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525704 | REC_0012112 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 17.7 | 67 | female | 1 | 6 | 4.8 | 4 | entrectinib 600 mg daily | 6.8 | false | MSS | 2026-03-15T05:35:59.892228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743925 | REC_0012113 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 15.8 | 82 | female | 1 | 22 | 5.4 | 6 | pembrolizumab 200 mg q3w | 7.5 | false | MSS | 2026-03-15T05:35:59.892483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149258 | REC_0012114 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 28 | 8.1 | 73 | male | 1 | 14 | 6 | 0 | osimertinib 80 mg daily | 40 | false | MSS | 2026-03-15T05:35:59.892733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_710845 | REC_0012115 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 10.7 | 70 | female | 2 | 9 | 2.2 | 5 | sotorasib 960 mg daily | 11.6 | false | MSI-H | 2026-03-15T05:35:59.892979+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239250 | REC_0012116 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 15.4 | 65 | female | 0 | 18 | 5.2 | 2 | osimertinib 80 mg daily | 19.7 | true | MSI-H | 2026-03-15T05:35:59.893234+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577550 | REC_0012117 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 18.1 | 67 | female | 0 | 18 | 4.3 | 2 | osimertinib 80 mg daily | 16.6 | true | MSI-H | 2026-03-15T05:35:59.893601+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527840 | REC_0012118 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 10.9 | 81 | male | 1 | 18 | 5.8 | 2 | osimertinib 80 mg daily | 15.2 | false | MSI-H | 2026-03-15T05:35:59.893862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714546 | REC_0012119 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 17 | 6.1 | 66 | female | 0 | 16 | 5.7 | 1 | pembrolizumab 200 mg q3w | 16.2 | false | MSS | 2026-03-15T05:35:59.894110+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158680 | REC_0012120 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 35 | 2.4 | 71 | female | 1 | 49 | 3.5 | 3 | carboplatin + paclitaxel + pembrolizumab | 19.4 | true | MSS | 2026-03-15T05:35:59.894361+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402449 | REC_0012121 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 16.9 | 83 | female | 2 | 19 | 5.3 | 6 | osimertinib 80 mg daily | 7.2 | true | MSI-H | 2026-03-15T05:35:59.894610+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525307 | REC_0012122 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 12.1 | 68 | female | 1 | 24 | 5.3 | 6 | osimertinib 80 mg daily | 12.6 | true | MSI-H | 2026-03-15T05:35:59.894861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934498 | REC_0012123 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 7.6 | 63 | female | 0 | 42 | 4.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 17.5 | true | MSS | 2026-03-15T05:35:59.895185+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872474 | REC_0012124 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 17.7 | 80 | female | 2 | 13 | 3.4 | 2 | osimertinib 80 mg daily | 21.6 | true | MSI-H | 2026-03-15T05:35:59.895433+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_594320 | REC_0012125 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 11 | 70 | female | 2 | 17 | 5.8 | 5 | osimertinib 80 mg daily | 6.7 | true | MSS | 2026-03-15T05:35:59.895679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_889969 | REC_0012126 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 15.6 | 72 | female | 1 | 29 | 6.6 | 4 | osimertinib 80 mg daily | 4.6 | false | MSS | 2026-03-15T05:35:59.895923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_241264 | REC_0012127 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 16.1 | 60 | male | 1 | 9 | 7.2 | 7 | osimertinib 80 mg daily | 9.1 | true | MSI-H | 2026-03-15T05:35:59.896227+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390256 | REC_0012128 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 13.7 | 75 | female | 2 | 9 | 6.5 | 6 | alectinib 600 mg BID | 19.5 | true | MSS | 2026-03-15T05:35:59.896488+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_115768 | REC_0012129 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 12.1 | 59 | male | 0 | 13 | 4 | 2 | entrectinib 600 mg daily | 23.5 | true | MSS | 2026-03-15T05:35:59.896738+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871990 | REC_0012130 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 30 | 3.7 | 69 | female | 1 | 20 | 4.4 | 1 | pembrolizumab 200 mg q3w | 16.2 | false | MSS | 2026-03-15T05:35:59.897088+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660445 | REC_0012131 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 10.7 | 61 | male | 1 | 17 | 7 | 6 | sotorasib 960 mg daily | 9 | true | MSS | 2026-03-15T05:35:59.897334+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685314 | REC_0012132 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 35 | 12.6 | 70 | female | 2 | 24 | 5 | 1 | entrectinib 600 mg daily | 19.9 | false | MSI-H | 2026-03-15T05:35:59.897569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_894395 | REC_0012133 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 22 | 5.2 | 68 | female | 1 | 21 | 6.8 | 0 | pembrolizumab 200 mg q3w | 34 | true | MSS | 2026-03-15T05:35:59.897800+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802216 | REC_0012134 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 16.6 | 72 | female | 2 | 13 | 6.2 | 5 | entrectinib 600 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.898032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686699 | REC_0012135 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 9.5 | 59 | female | 0 | 11 | 5 | 6 | osimertinib 80 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:59.898265+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_669028 | REC_0012136 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 11.1 | 70 | female | 1 | 13 | 5.2 | 2 | entrectinib 600 mg daily | 17.9 | false | MSI-H | 2026-03-15T05:35:59.898502+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846516 | REC_0012137 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 10.8 | 67 | female | 0 | 7 | 5.8 | 1 | entrectinib 600 mg daily | 17.3 | true | MSI-H | 2026-03-15T05:35:59.898743+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_950328 | REC_0012138 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 12.6 | 61 | male | 0 | 7 | 7.3 | 2 | sotorasib 960 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:59.898989+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_260415 | REC_0012139 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 25 | 9.3 | 69 | female | 1 | 15 | 5.3 | 0 | sotorasib 960 mg daily | 44 | false | MSS | 2026-03-15T05:35:59.899218+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327395 | REC_0012140 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 10.7 | 78 | female | 1 | 15 | 3.7 | 1 | osimertinib 80 mg daily | 16.6 | true | MSI-H | 2026-03-15T05:35:59.899448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_516266 | REC_0012141 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 8.6 | 84 | female | 3 | 10 | 5.9 | 2 | entrectinib 600 mg daily | 15 | true | MSS | 2026-03-15T05:35:59.899676+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529139 | REC_0012142 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 11.9 | 74 | female | 1 | 9 | 3.9 | 6 | osimertinib 80 mg daily | 8.9 | false | MSI-H | 2026-03-15T05:35:59.899908+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_822101 | REC_0012143 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 19 | 3.4 | 61 | female | 0 | 44 | 4.9 | 2 | pembrolizumab 200 mg q3w | 19.9 | true | MSS | 2026-03-15T05:35:59.900289+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740604 | REC_0012144 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 10.7 | 55 | female | 0 | 28 | 5.7 | 2 | sotorasib 960 mg daily | 18.9 | false | MSS | 2026-03-15T05:35:59.900535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_489526 | REC_0012145 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 9.8 | 79 | female | 3 | 14 | 5.3 | 4 | alectinib 600 mg BID | 8.8 | false | MSS | 2026-03-15T05:35:59.900779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_523594 | REC_0012146 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 11.6 | 65 | male | 0 | 13 | 5.6 | 4 | osimertinib 80 mg daily | 11.7 | true | MSI-H | 2026-03-15T05:35:59.901015+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291038 | REC_0012147 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 18.3 | 74 | female | 2 | 15 | 5.7 | 7 | sotorasib 960 mg daily | 20.1 | true | MSS | 2026-03-15T05:35:59.901247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_592298 | REC_0012148 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 7.4 | 66 | female | 1 | 19 | 4.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.4 | false | MSS | 2026-03-15T05:35:59.901476+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332598 | REC_0012149 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 13 | 13.2 | 74 | female | 0 | 4 | 6.8 | 0 | sotorasib 960 mg daily | 43 | true | MSS | 2026-03-15T05:35:59.901708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634724 | REC_0012150 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 14 | 3.4 | 75 | female | 2 | 12 | 3.5 | 2 | entrectinib 600 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.901938+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458796 | REC_0012151 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 7.7 | 65 | male | 0 | 7 | 4.7 | 5 | entrectinib 600 mg daily | 15.7 | false | MSS | 2026-03-15T05:35:59.902169+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_131281 | REC_0012152 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 8.8 | 56 | male | 1 | 17 | 2.6 | 1 | alectinib 600 mg BID | 16.9 | false | MSS | 2026-03-15T05:35:59.902400+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246783 | REC_0012153 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 24 | 4.5 | 59 | female | 1 | 20 | 5.2 | 0 | osimertinib 80 mg daily | 27.6 | true | MSS | 2026-03-15T05:35:59.902630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626222 | REC_0012154 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 15 | 13.5 | 75 | male | 0 | 21 | 6.1 | 6 | alectinib 600 mg BID | 18.7 | false | MSI-H | 2026-03-15T05:35:59.902865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462244 | REC_0012155 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 14 | 66 | female | 1 | 23 | 7.5 | 7 | entrectinib 600 mg daily | 12.7 | true | MSS | 2026-03-15T05:35:59.903098+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379110 | REC_0012156 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 12.7 | 79 | female | 2 | 10 | 4.8 | 6 | pembrolizumab 200 mg q3w | 8.4 | false | MSS | 2026-03-15T05:35:59.903378+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_909625 | REC_0012157 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 16.4 | 66 | female | 0 | 6 | 5 | 5 | entrectinib 600 mg daily | 9.2 | false | MSS | 2026-03-15T05:35:59.903622+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221872 | REC_0012158 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 12.1 | 77 | female | 2 | 9 | 5.3 | 6 | entrectinib 600 mg daily | 7 | false | MSS | 2026-03-15T05:35:59.903857+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915280 | REC_0012159 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 8.7 | 60 | female | 1 | 15 | 4.4 | 7 | osimertinib 80 mg daily | 8.1 | true | MSS | 2026-03-15T05:35:59.904133+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_279569 | REC_0012160 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 9.6 | 72 | female | 3 | 22 | 5.8 | 1 | osimertinib 80 mg daily | 20.4 | false | MSS | 2026-03-15T05:35:59.904372+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114126 | REC_0012161 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 9.6 | 62 | female | 1 | 21 | 6.1 | 2 | alectinib 600 mg BID | 15.8 | false | MSS | 2026-03-15T05:35:59.904608+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747770 | REC_0012162 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 5.9 | 63 | male | 0 | 16 | 6.7 | 1 | pembrolizumab 200 mg q3w | 28.4 | true | MSS | 2026-03-15T05:35:59.904839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221222 | REC_0012163 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 3.6 | 71 | male | 2 | 18 | 4.2 | 2 | osimertinib 80 mg daily | 14.8 | false | MSS | 2026-03-15T05:35:59.905075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_216784 | REC_0012164 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 10.6 | 60 | female | 0 | 16 | 4.2 | 4 | sotorasib 960 mg daily | 8.2 | true | MSI-H | 2026-03-15T05:35:59.905311+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_689284 | REC_0012165 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 10.1 | 72 | female | 0 | 30 | 4.9 | 5 | entrectinib 600 mg daily | 15.1 | true | MSI-H | 2026-03-15T05:35:59.905542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_170472 | REC_0012166 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 19 | 7.4 | 67 | male | 0 | 49 | 5.6 | 5 | pembrolizumab 200 mg q3w | 11.1 | true | MSS | 2026-03-15T05:35:59.905771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934416 | REC_0012167 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 12 | 70 | female | 1 | 15 | 6 | 6 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.906007+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122108 | REC_0012168 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 17.9 | 64 | male | 1 | 12 | 6.8 | 7 | entrectinib 600 mg daily | 17.3 | true | MSI-H | 2026-03-15T05:35:59.906240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_419149 | REC_0012169 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 16 | 14.2 | 68 | female | 1 | 11 | 4.3 | 2 | osimertinib 80 mg daily | 17.7 | true | MSI-H | 2026-03-15T05:35:59.906542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_595831 | REC_0012170 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 13.3 | 53 | female | 0 | 20 | 8 | 7 | entrectinib 600 mg daily | 8.9 | false | MSI-H | 2026-03-15T05:35:59.906785+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_241567 | REC_0012171 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 27 | 13.5 | 70 | female | 2 | 14 | 6.4 | 0 | osimertinib 80 mg daily | 9.8 | false | MSI-H | 2026-03-15T05:35:59.907018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752016 | REC_0012172 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 6.2 | 75 | female | 2 | 7 | 5.5 | 1 | entrectinib 600 mg daily | 14.9 | false | MSS | 2026-03-15T05:35:59.907253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267732 | REC_0012173 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 7.8 | 66 | female | 1 | 10 | 6 | 7 | sotorasib 960 mg daily | 9.1 | false | MSS | 2026-03-15T05:35:59.907481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113126 | REC_0012174 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 8.7 | 53 | female | 0 | 64 | 3.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.2 | false | MSS | 2026-03-15T05:35:59.907713+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207227 | REC_0012175 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 12 | 3 | 58 | male | 0 | 33 | 5.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.8 | true | MSS | 2026-03-15T05:35:59.907948+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_847305 | REC_0012176 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 13.1 | 67 | female | 1 | 16 | 5.8 | 6 | alectinib 600 mg BID | 12 | true | MSI-H | 2026-03-15T05:35:59.908210+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356718 | REC_0012177 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 12.6 | 76 | female | 2 | 6 | 5.3 | 2 | alectinib 600 mg BID | 26.6 | false | MSI-H | 2026-03-15T05:35:59.908446+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907526 | REC_0012178 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 5.2 | 70 | female | 1 | 14 | 4.7 | 6 | entrectinib 600 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:59.908677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339700 | REC_0012179 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 7.9 | 57 | male | 1 | 12 | 5.4 | 1 | alectinib 600 mg BID | 21.9 | true | MSS | 2026-03-15T05:35:59.908910+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652323 | REC_0012180 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 12.8 | 76 | male | 1 | 15 | 5.1 | 1 | entrectinib 600 mg daily | 16.8 | false | MSI-H | 2026-03-15T05:35:59.909154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_742650 | REC_0012181 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 18.1 | 67 | male | 1 | 18 | 6.4 | 3 | osimertinib 80 mg daily | 13.3 | false | MSS | 2026-03-15T05:35:59.909397+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794450 | REC_0012182 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 24 | 12.8 | 60 | male | 0 | 15 | 6.1 | 0 | osimertinib 80 mg daily | 33.5 | false | MSI-H | 2026-03-15T05:35:59.909718+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_992053 | REC_0012183 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 14.1 | 71 | female | 2 | 2 | 5.7 | 5 | alectinib 600 mg BID | 10.2 | false | MSS | 2026-03-15T05:35:59.909983+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_551509 | REC_0012184 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 14 | 13.4 | 71 | female | 3 | 19 | 4.7 | 4 | osimertinib 80 mg daily | 17.6 | true | MSI-H | 2026-03-15T05:35:59.910241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_710158 | REC_0012185 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 10.2 | 78 | male | 1 | 4 | 6 | 1 | entrectinib 600 mg daily | 29.3 | false | MSS | 2026-03-15T05:35:59.910503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256469 | REC_0012186 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 12.2 | 75 | female | 0 | 18 | 2.8 | 3 | sotorasib 960 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:35:59.910748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462444 | REC_0012187 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 14.3 | 66 | female | 0 | 13 | 7.6 | 4 | alectinib 600 mg BID | 12.9 | true | MSS | 2026-03-15T05:35:59.910989+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614577 | REC_0012188 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 3.2 | 70 | female | 2 | 38 | 5.1 | 5 | pembrolizumab 200 mg q3w | 13.3 | false | MSS | 2026-03-15T05:35:59.911216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423272 | REC_0012189 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 13 | 8.5 | 74 | female | 2 | 8 | 5 | 5 | osimertinib 80 mg daily | 8.1 | true | MSS | 2026-03-15T05:35:59.911446+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166305 | REC_0012190 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 15 | 10.1 | 74 | female | 3 | 52 | 3.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.2 | false | MSS | 2026-03-15T05:35:59.911682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532110 | REC_0012191 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 12.7 | 74 | female | 2 | 28 | 5.9 | 1 | osimertinib 80 mg daily | 7.8 | false | MSS | 2026-03-15T05:35:59.911915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_279594 | REC_0012192 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 9.3 | 71 | female | 2 | 10 | 5.6 | 2 | osimertinib 80 mg daily | 23.3 | false | MSS | 2026-03-15T05:35:59.912202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_365145 | REC_0012193 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 34 | 16.9 | 65 | male | 1 | 13 | 5.8 | 7 | pembrolizumab 200 mg q3w | 8.6 | true | MSS | 2026-03-15T05:35:59.912462+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250222 | REC_0012194 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 31 | 6.9 | 69 | female | 0 | 20 | 4.5 | 6 | pembrolizumab 200 mg q3w | 23.2 | true | MSS | 2026-03-15T05:35:59.912692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_130389 | REC_0012195 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 7.8 | 58 | female | 1 | 18 | 5.7 | 2 | pembrolizumab 200 mg q3w | 16.7 | false | MSS | 2026-03-15T05:35:59.913014+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140277 | REC_0012196 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 10.6 | 71 | female | 1 | 14 | 4.8 | 3 | osimertinib 80 mg daily | 16.2 | true | MSI-H | 2026-03-15T05:35:59.913253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940507 | REC_0012197 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 16 | 12.6 | 59 | male | 0 | 11 | 7 | 1 | sotorasib 960 mg daily | 18.6 | false | MSS | 2026-03-15T05:35:59.913493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539518 | REC_0012198 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.1 | 69 | female | 0 | 21 | 5.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.5 | false | MSS | 2026-03-15T05:35:59.913721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_920811 | REC_0012199 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 5.8 | 74 | female | 0 | 72 | 7.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.5 | true | MSS | 2026-03-15T05:35:59.913952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_399410 | REC_0012200 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 8 | 59 | female | 0 | 47 | 8.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.8 | false | MSS | 2026-03-15T05:35:59.914187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.